Content
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Article By:
Lorimer Wilson
Read
Monday, February 19, 2024 12:05 AM EDT
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Article By:
Lorimer Wilson
Read
Sunday, February 18, 2024 6:14 PM EDT
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
Article By:
ChinaBio® Today
Read
Saturday, February 17, 2024 2:20 PM EDT
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
Article By:
Jim Van Meerten
Read
Tuesday, February 13, 2024 12:06 PM EDT
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
In this article: IRWD
Micro Marvel - Y-Mabs Therapeutics
Article By:
Jim Van Meerten
Read
Tuesday, February 13, 2024 5:30 AM EDT
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year.
In this article: YMAB
Gilead Sciences Stock Approaches Daily Buying Area
Article By:
Elliottwave Forecast
Read
Monday, February 12, 2024 7:16 AM EDT
Gilead Sciences, Inc. is an US American biopharmaceutical company. It focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir and sofosbuvir.
In this article: GILD
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Article By:
ChinaBio® Today
Read
Sunday, February 11, 2024 12:40 PM EDT
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
LLY Vs NVO: Which One Is Likely To Become A $1T Company First
Article By:
The Tokenist
Read
Thursday, February 8, 2024 5:06 AM EDT
Tackling growing waistlines is expected to yield much shareholder value.
MicroMarvel - ORIC Pharmaceutical - Fights Cancer
Article By:
Jim Van Meerten
Read
Wednesday, February 7, 2024 2:12 PM EDT
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers in the United States.
In this article: ORIC
Fusion Pharmaceuticals - Already Discovered By Wall Street
Article By:
Jim Van Meerten
Read
Tuesday, February 6, 2024 2:07 PM EDT
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.
In this article: FUSN
MicroMarvel: MacroGenics Confuses Wall Street
Article By:
Jim Van Meerten
Read
Monday, February 5, 2024 11:29 AM EDT
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
In this article: MGNX
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Article By:
ChinaBio® Today
Read
Saturday, February 3, 2024 2:40 PM EDT
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Tarsus Pharmaceuticals - Mixed Projections
Article By:
Jim Van Meerten
Read
Friday, February 2, 2024 11:36 AM EDT
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
In this article: TARS
